A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis.

ABSTRACT:

Background

One of the hallmarks of NF2-related Schwannomatosis (NF2-related SWN) is bilateral vestibular schwannomas (VS) that can cause progressive hearing impairment in patients. This systematic review was performed to investigate the efficacy and toxicity of tested targeted agents.

Methods

The systematic search was conducted on PubMed and EMBASE Ovid databases from inception to October 2022, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The incidence of outcomes in studies involving bevacizumab and other targeted therapies was extracted. The bevacizumab results were pooled, and 95% confidence intervals (95% CI) were calculated.

Results

Sixteen studies (8 prospective and 8 retrospective) testin

SUBMITTER: Chiranth S 

PROVIDER: S-EPMC10496940 | biostudies-literature | 2023 Jan-Dec

REPOSITORIES: biostudies-literature